Lista de obras -

A Cell Culture-Derived Influenza Vaccine Provides Consistent Protection Against Infection and Reduces the Duration and Severity of Disease in Infected Individuals ⬇️

artículo científico publicado el 19 de enero de 2012

A Pandemic Influenza H1N1 Live Vaccine Based on Modified Vaccinia Ankara Is Highly Immunogenic and Protects Mice in Active and Passive Immunizations ⬇️

artículo científico publicado el 16 de agosto de 2010

A Vero Cell–Derived Whole-Virus H5N1 Vaccine Effectively Induces Neuraminidase-Inhibiting Antibodies ⬇️

artículo científico publicado el 16 de noviembre de 2011

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

artículo científico publicado en 2009

A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination ⬇️

artículo científico publicado el 29 de junio de 2012

A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate ⬇️

artículo científico publicado el 10 de mayo de 2012

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

artículo científico publicado en 2008

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

artículo científico publicado en 2005

A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccines.

artículo científico publicado en 2005

A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory

artículo científico publicado el 28 de julio de 2012

A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production.

artículo científico publicado en 1999

A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.

artículo científico publicado en 2010

An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system

artículo científico publicado en 2010

Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.

artículo científico publicado en 2012

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

artículo científico publicado en 2007

Clinical development of a Vero cell culture-derived seasonal influenza vaccine ⬇️

artículo científico publicado el 13 de diciembre de 2011

Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model.

artículo científico publicado en 2009

Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

scientific article published on 27 February 2009

Development of a Vero cell-derived influenza whole virus vaccine.

artículo científico publicado en 1999

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine ⬇️

artículo científico publicado el 1 de mayo de 1998

Development of a novel influenza vaccine derived from a continuous cell line

artículo científico publicado en 2001

Differential phosphorylation of the nucleoprotein of influenza A viruses

artículo científico publicado en 1989

Effective poxvirus removal by sterile filtration during manufacture of plasma derivatives

artículo científico publicado en 2005

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial ⬇️

artículo científico publicado el 15 de febrero de 2011

Emerging Influenza Strains in the Last Two Decades: A Threat of a New Pandemic?

artículo científico publicado en 2015

Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.

artículo científico publicado en 2010

H5N1 influenza virus and the safety of plasma products.

artículo científico publicado en 2007

H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model

artículo científico publicado en 2011

High level expression of active human prothrombin in a vaccinia virus expression system

artículo científico publicado el 3 de agosto de 1992

How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions

scientific article published on 21 June 2019

Humoral and cell-mediated immunity to vero cell-derived influenza vaccine

artículo científico publicado en 2000

Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs.

artículo científico publicado en 2015

In vitro and in vivo anti-retroviral activity of the substance purified from the aqueous extract of Chelidonium majus L.

artículo científico publicado en 2006

Influenza Anti-Stalk Antibodies: Development of a New Method for the Evaluation of the Immune Responses to Universal Vaccine

scientific article published on 24 January 2020

Influenza D Virus: Serological Evidence in the Italian Population from 2005 to 2017

artículo científico publicado en 2019

Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model

artículo científico publicado en 2012

Natural IgM Antibodies in Baby Rabbit Serum Bind High-Mannose Glycans on HIV Type 1 Glycoprotein 120/160 and Activate Classic Complement Pathway ⬇️

artículo científico publicado el 1 de mayo de 1998

Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients

artículo científico publicado en 2014

Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.

artículo científico publicado en 2009

Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.

artículo científico publicado en 2014

Phosphopeptide fingerprints of nucleoproteins of various influenza A virus strains grown in different host cells

artículo científico publicado en 1985

Polymeric lamellar substrate particles for intranasal vaccination

artículo científico publicado en 2001

Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines.

artículo científico publicado en 2008

Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.

artículo científico publicado en 2012

Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines

artículo científico publicado en 2013

Production of highly homogeneous and structurally intact recombinant von Willebrand factor multimers by furin-mediated propeptide removal in vitro

scientific article published on 01 December 1996

Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.

artículo científico publicado en 2013

Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial

artículo científico publicado en 2011

Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine

artículo científico publicado en 2011

Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination

artículo científico publicado en 2009

Serologically-Based Evaluation of Cross-Protection Antibody Responses among Different A(H1N1) Influenza Strains

artículo científico publicado en 2020

Seroprevalence study of Toscana virus and viruses belonging to the Sandfly fever Naples antigenic complex in central and southern Italy.

artículo científico publicado en 2017

Superior in vitro stimulation of human CD8+ T-cells by whole virus versus split virus influenza vaccines.

artículo científico publicado en 2014

The nucleoprotein as a possible major factor in determining host specificity of influenza H3N2 viruses

scientific article published on 01 December 1985

The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans

artículo científico publicado en 2007

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.

artículo científico publicado en 2009

Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases

artículo científico

West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data

artículo científico publicado en 2003

[Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities]

artículo científico publicado en 1991

[Vaccine protection in the elderly: are Austrian seniors adequately protected by vaccinations?]

artículo científico publicado en 2002

Lista de obras de

A Cell Culture-Derived Influenza Vaccine Provides Consistent Protection Against Infection and Reduces the Duration and Severity of Disease in Infected Individuals ⬇️

A Pandemic Influenza H1N1 Live Vaccine Based on Modified Vaccinia Ankara Is Highly Immunogenic and Protects Mice in Active and Passive Immunizations ⬇️

A Vero Cell–Derived Whole-Virus H5N1 Vaccine Effectively Induces Neuraminidase-Inhibiting Antibodies ⬇️

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination ⬇️

A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate ⬇️

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccines.

A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory

A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production.

A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.

An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system

Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

Clinical development of a Vero cell culture-derived seasonal influenza vaccine ⬇️

Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model.

Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

Development of a Vero cell-derived influenza whole virus vaccine.

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine ⬇️

Development of a novel influenza vaccine derived from a continuous cell line

Differential phosphorylation of the nucleoprotein of influenza A viruses

Effective poxvirus removal by sterile filtration during manufacture of plasma derivatives

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial ⬇️

Emerging Influenza Strains in the Last Two Decades: A Threat of a New Pandemic?

Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.

H5N1 influenza virus and the safety of plasma products.

H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model

High level expression of active human prothrombin in a vaccinia virus expression system

How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions

Humoral and cell-mediated immunity to vero cell-derived influenza vaccine

Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs.

In vitro and in vivo anti-retroviral activity of the substance purified from the aqueous extract of Chelidonium majus L.

Influenza Anti-Stalk Antibodies: Development of a New Method for the Evaluation of the Immune Responses to Universal Vaccine

Influenza D Virus: Serological Evidence in the Italian Population from 2005 to 2017

Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model

Natural IgM Antibodies in Baby Rabbit Serum Bind High-Mannose Glycans on HIV Type 1 Glycoprotein 120/160 and Activate Classic Complement Pathway ⬇️

Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients

Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.

Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.

Phosphopeptide fingerprints of nucleoproteins of various influenza A virus strains grown in different host cells

Polymeric lamellar substrate particles for intranasal vaccination

Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines.

Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.

Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines

Production of highly homogeneous and structurally intact recombinant von Willebrand factor multimers by furin-mediated propeptide removal in vitro

Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.

Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial

Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine

Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination

Serologically-Based Evaluation of Cross-Protection Antibody Responses among Different A(H1N1) Influenza Strains

Seroprevalence study of Toscana virus and viruses belonging to the Sandfly fever Naples antigenic complex in central and southern Italy.

Superior in vitro stimulation of human CD8+ T-cells by whole virus versus split virus influenza vaccines.

The nucleoprotein as a possible major factor in determining host specificity of influenza H3N2 viruses

The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.

Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases

West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data

[Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities]

[Vaccine protection in the elderly: are Austrian seniors adequately protected by vaccinations?]